RESUMEN
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours. Standard treatment is surgical resection. Following complete resection of the primary tumour, patients with PPGL are at risk of developing new tumoural events. The present guideline aims to propose standardised clinical care of long-term follow-up in patients operated on for a PPGL. The guideline has been developed by The European Society of Endocrinology and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles. We performed a systematic review of the literature and analysed the European Network for the Study of Adrenal Tumours (ENS@T) database. The risk of new events persisted in the long term and was higher for patients with genetic or syndromic diseases. Follow-up in the published cohorts and in the ENS@T database was neither standardised nor exhaustive, resulting in a risk of follow-up bias and in low statistical power beyond 10 years after complete surgery. To inform patients and care providers in this context of low-quality evidence, the Guideline Working Group therefore prepared recommendations on the basis of expert consensus. Key recommendations are the following: we recommend that all patients with PPGL be considered for genetic testing; we recommend assaying plasma or urinary metanephrines every year to screen for local or metastatic recurrences or new tumours; and we suggest follow-up for at least 10 years in all patients operated on for a PPGL. High-risk patients (young patients and those with a genetic disease, a large tumour and/or a paraganglioma) should be offered lifelong annual follow-up.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/terapia , Endocrinología/normas , Paraganglioma/terapia , Feocromocitoma/terapia , Guías de Práctica Clínica como Asunto/normas , Sociedades Médicas/normas , Neoplasias de las Glándulas Suprarrenales/cirugía , Europa (Continente) , Humanos , Paraganglioma/cirugía , Feocromocitoma/cirugíaRESUMEN
Hypertension is a common health problem with serious consequences for individuals and a heavy attributable burden for populations. Reducing this burden requires preventive actions at the population level and early diagnosis at the individual level, followed by proactive interventions with proven benefits. Given the variability of blood pressure measurement, diagnosis is established only after repeated measurements under standardized conditions, if possible outside the clinic. Lifestyle changes can modestly reduce blood pressure; their impact is significant if they can be achieved on a large scale. Hypertension treatment requires a rational pharmacological approach, which can reach the target blood pressure within less than 6 months and three pharmacological classes at most in more than 80% of cases. Specialized consultation is required in the remaining 20% to detect secondary hypertensions, to optimize drug therapy and to discuss, in a minority of cases, non-pharmacological treatments. Recommendations are written by experts who select, interpret, and extrapolate the results of clinical research. As a consequence, they are sometimes unsuitable for primary care practice and frequently inconsistent across guidelines. Efforts are currently made to produce less disputable and more usable guidelines.
Asunto(s)
Hipertensión/terapia , Edad de Inicio , Antihipertensivos/uso terapéutico , Determinación de la Presión Sanguínea/métodos , Humanos , Higiene , Hipertensión/diagnóstico , Hipertensión/epidemiología , Hipertensión/etiología , Estilo de VidaRESUMEN
Radiofrequency-induced renal ablation is a non-pharmacologic therapeutic approach for the treatment of essential resistant hypertension, with a stable blood pressure lowering effect. However, data from published studies cannot conclude yet on the long-term efficacy and safety of the procedure. Therefore, the various techniques of renal nerve ablation (radiofrequency, cryoablation, ultrasounds) need further evaluation in clinical research trials. According to recent national and international recommendations, renal ablation should be reserved for patients with essential resistant hypertension.
Asunto(s)
Desnervación/métodos , Procedimientos Endovasculares/métodos , Hipertensión/cirugía , Riñón/inervación , Técnicas de Ablación , Ablación por Catéter , Hipertensión Esencial , Humanos , Sistema Nervioso SimpáticoRESUMEN
Endocrine hypertension is the most common cause of secondary hypertension affecting ~3 % of the population, with primary hyperaldosteronism and pheochromocytoma being the principal conditions. Both diseases share an increased cardiovascular risk in comparison with essential hypertension patients (at the same blood pressure level). This augmented cardiovascular risk as well as the availability of specific treatment emphasize the importance of timely and correct diagnosis. Primary hyperaldosteronism, representing one tenth of hypertensive patients, is an under-diagnosed disease partly because of difficult diagnostic steps and absence of standard criteria. Recently, the description of somatic mutations in KCNJ5 gene in Conn adenomas had precipitated a resurgence of research activity to understand the pathophysiology of this common disease. Research had confirmed the role of these mutations in aldosterone hypersecretion; however, its role in adenoma formation is still to be elucidated. Elsewhere, much remains to be done in order to understand the pathogenesis of bilateral idiopathic hyperaldosteronism, the other common subtype of primary hyperaldosteronism. In pheochromocytoma, the revolution of genetics has led to major advances in the characterization of this rare disease. It is now clear that up to 50 % of patients with pheochromocytoma have a genetic abnormality and that different pheochromocytomas segregate into two clusters with distinct genotypes, signal transduction pathways and expression of biomarkers (phenotype). This continuing progress has huge effects on patient's management and follow-up. In this article we will shed light on the recent developments in both diseases with emphasis on their role in patient care.
Asunto(s)
Enfermedades del Sistema Endocrino/complicaciones , Hipertensión/etiología , Neoplasias de las Glándulas Suprarrenales/complicaciones , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/genética , Adenoma Corticosuprarrenal/complicaciones , Adenoma Corticosuprarrenal/diagnóstico , Adenoma Corticosuprarrenal/genética , Aldosterona/metabolismo , Enfermedades Cardiovasculares , Humanos , Hiperaldosteronismo/complicaciones , Hiperaldosteronismo/diagnóstico , Hiperaldosteronismo/genética , Mutación , Feocromocitoma/complicaciones , Feocromocitoma/diagnóstico , Feocromocitoma/genética , Factores de RiesgoRESUMEN
Aldosterone hypersecretion in primary aldosteronism is unilateral (aldosterone producing adenoma and primary unilateral hyperplasia) or bilateral (idiopathic adrenal hyperplasia). Laparoscopic adrenalectomy is nowadays the preferred approach to treat patients with unilateral primary aldosteronism. We review the outcomes of this intervention in recently published series. Laparoscopic adrenalectomy has a morbidity of 5-14%, mortality below 1%, and a mean hospital stay around 3 days. It generally results in the normalization of aldosterone secretion and in a large decrease of blood pressure and antihypertensive medication, but normotension without treatment is only achieved in 42% of all cases. Normotension following adrenalectomy is more likely in young and lean women with recent low grade hypertension than in obese men with long-standing high grade hypertension or a family history of hypertension. However, individual prediction of the blood pressure outcome is not accurate and predictors of hypertension cure should not be used to select patients for surgery. Age, associated health conditions and preferences of the patient are more relevant to this end.
Asunto(s)
Adrenalectomía , Hiperaldosteronismo/cirugía , Adrenalectomía/efectos adversos , Femenino , Humanos , Hiperaldosteronismo/mortalidad , Hiperaldosteronismo/terapia , Masculino , Resultado del TratamientoRESUMEN
Patients with pheochromocytoma or paraganglioma are at risk of developing tumor recurrences or new tumors after successful resection of the primary tumor. This review summarizes current knowledge concerning the incidence and risk factors for such events. The overall incidence exceeds 15%. Patients with inherited tumors have a higher probability of recurrence or new tumors. Most recurrences are metastatic, particularly in patients with SDHB mutations or nonhereditary tumors. We recommend the determination of plasma or urinary metanephrines (normetanephrine and metanephrine) 1 month after surgery. In patients with sporadic, single tumors ≤5 cm in diameter, clinical and biochemical follow-up should be performed every 2 years. However, this follow-up period can be reduced to yearly, if it is more simple and more convenient for patients and physicians. Patients with larger or multiple but apparently benign tumors and/or inherited disease should be tested 6 months after surgery and then every year for the rest of their lives. Imaging follow-up is also required in patients with inherited or malignant tumors.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/cirugía , Feocromocitoma/cirugía , Cuidados Posoperatorios , Complicaciones Posoperatorias/epidemiología , Neoplasias de las Glándulas Suprarrenales/enfermería , Neoplasias de las Glándulas Suprarrenales/patología , Estudios de Seguimiento , Humanos , Metanefrina/sangre , Paraganglioma/enfermería , Paraganglioma/patología , Paraganglioma/cirugía , Feocromocitoma/enfermería , Feocromocitoma/patología , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/etiologíaRESUMEN
Metastatic pheochromocytomas and paragangliomas are rare and challenging tumors. The tumor burden, combined with excessive catecholamine production, predispose to a broad spectrum of complications that range from spinal cord compression to any organ damage, all of which may lead to decreased quality of life and overall survival. Current therapies include surgery, systemic chemotherapy and radiopharmaceutical agents. Surgery is often a preferred therapy because it may cure or allow a long-term remission in patients with locoregional or isolated resectable distant metastases. Additionally, surgery can palliate symptoms related to tumor burden or catecholamine excess. However, in patients for whom surgery is not an option, systemic chemotherapy and radiopharmaceutical agents are preferred options. Systemic chemotherapy and radiopharmaceutical agents such as 131I-Metaiodobenzylguanidine (131I-MIBG) may cause partial responses or stabilization of disease with better blood pressure control and symptomatic and performance status improvement. However, as these therapies are only palliative, patients' quality of life and personal preferences should always be considered. The recognition of molecular pathways involved in the pheochromocytoma and paraganglioma tumorigenesis has driven the development of new therapeutic options. Agents such as tyrosine kinase, MAPK, PI3K, or hypoxia inducible factor inhibitors, alone or in combination, may represent novel therapeutic strategies that could be evaluated in prospective clinical trials. Transcriptional profiling and the development of personalized cancer medicine will help to pave the way for more specific therapeutic approaches and combinations.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/terapia , Feocromocitoma/terapia , Neoplasias de las Glándulas Suprarrenales/genética , Neoplasias de las Glándulas Suprarrenales/radioterapia , Neoplasias de las Glándulas Suprarrenales/cirugía , Animales , Humanos , Terapia Molecular Dirigida , Metástasis de la Neoplasia , Paraganglioma/genética , Paraganglioma/radioterapia , Paraganglioma/cirugía , Paraganglioma/terapia , Feocromocitoma/genética , Feocromocitoma/radioterapia , Feocromocitoma/cirugíaRESUMEN
This review aims to describe the role and the results of catheter-based renal nerve ablation for the treatment of resistant hypertension. Despite the availability of multiple classes of orally active antihypertensive treatments, resistant hypertension remains an important public health issue in 2012 due to its prevalence and association with target-organ damage and poor prognosis. The failure of purely pharmacological approaches to treat resistant hypertension has stimulated interest in invasive device-based treatments based on old concepts. In the absence of orally active antihypertensive agents, patients with severe and complicated hypertension were widely treated by surgical denervation of the kidney until the 1960s, but this approach was associated with a high incidence of severe adverse events and a high mortality rate. A new catheter system using radiofrequency energy has been developed, allowing an endovascular approach to renal denervation and providing patients with resistant hypertension with a new therapeutic option that is less invasive than surgery and can be performed rapidly under local anaesthesia. To date, this technique has been evaluated only in open-label trials including small numbers of highly selected resistant hypertensive patients with suitable renal artery anatomy. The available evidence suggests a favourable blood pressure-lowering effect in the short term (6 months) and a low incidence of immediate local and endovascular complications. This follow-up period is, however, too short for the detection of rare or late-onset adverse events. For the time being, the benefit/risk ratio of this technique remains to be evaluated, precluding its uncontrolled and widespread use in routine practice.
Asunto(s)
Ablación por Catéter/métodos , Hipertensión/cirugía , Riñón/inervación , Nervios Esplácnicos/cirugía , Simpatectomía/métodos , Animales , Antihipertensivos/uso terapéutico , Resistencia a Medicamentos , Humanos , Hipertensión/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Endocrine hypertension represents more than half of the causes of secondary hypertension. This entity encompasses several diseases including primary aldosteronism, paraganglioma/pheochromocytoma and Cushing's syndrome. The screening of endocrine hypertension should be performed in all the patients presenting with: (1) a resistant hypertension; (2) a severe hypertension; (3) the coexistence of hypertension with an adrenal adenoma, clinical or biological abnormalities. Clinical signs and symptoms, whenever present, lack specificity, especially for primary aldosteronism where hypertension is usually the unique symptom. Screening is performed by the measurement of several hormones and by a tomodensitometry to study the morphology of the adrenals: the presence of a solitary or multiples adenomas, or hyperplasia. Pheochromocytoma and Cushing's syndrome are very uncommon and should be referred to specialized centres. Primary aldosteronism is a frequent cause of secondary hypertension. Once the diagnosis is obtained, it is essential to differentiate whether it is a surgically correctable form or not. The patients with a bilateral adrenal hyperplasia can be managed effectively by mineralocorticoids receptor antagonist. The adrenalectomy will cure or improve hypertension for the majority of the patients with a lateralized secretion of aldosterone. The diagnosis and the treatment of these disorders can be challenging. However, the diagnosis of endocrine hypertension allows diagnosing surgical correctable form of hypertension, which is not possible in essential hypertension.
Asunto(s)
Enfermedades del Sistema Endocrino/complicaciones , Hipertensión/etiología , Neoplasias de las Glándulas Suprarrenales/complicaciones , Algoritmos , Síndrome de Cushing/complicaciones , Humanos , Hipertensión/diagnóstico , Síndrome de Exceso Aparente de Mineralocorticoides/complicaciones , Paraganglioma/complicaciones , Feocromocitoma/complicacionesRESUMEN
Recent evidence demonstrates an increased incidence of primary aldosteronism (PA) in approximately 10% of the hypertensive population, making noninvasive and simple screening methods necessary. The aim of the present study was to apply a time-resolved fluorescence immunoassay for the measurement of aldosterone in saliva and the establishment of a cut-off to identify patients with a high likelihood for PA requiring subsequent screening with the aldosterone to renin ratio. Saliva was collected (AM and PM) to ascertain an optimum time with best discriminating power between healthy and disease states. Plasma aldosterone, after overnight recumbency and 4 h later, was collected for posture testing. The participants included 53 PA patients (aged 14-78), 54 with essential hypertension (EH, aged 19-82), and 38 healthy volunteers (aged 19-56). Saliva aldosterone (SA) (median, 25-75(th)%) in PA was found at 90 pg/ml (61-139) compared to 53 pg/ml (40-85) in EH, with discrimination between PA versus EHs best in the morning (cutoff: 81 pg/ml, 77% sensitivity, 82% specificity). Saliva aldosterone decreases throughout the day in patients with adenomas [APA AM: 123 pg/ml (92-213) vs. PM: 79 pg/ml (41-116)], but not in those with bilateral hyperplasia [BAH AM: 85 pg/ml (59-115)] vs. pm 69 pg/ml (57-114). Morning SA alone allows discrimination between PA and controls, though with significant overlap against EHs, leading to a high number of false positives. More promising is the use of diurnal variation in SA in distinguishing between APA and BAH. The decline in SA seen in patients with APA presents a more constant finding compared to posture testing, which fails to correctly classify a large number of patients.
Asunto(s)
Aldosterona/análisis , Técnicas de Diagnóstico Endocrino , Hiperaldosteronismo/diagnóstico , Saliva/química , Adenoma/complicaciones , Adenoma/metabolismo , Adolescente , Corteza Suprarrenal/metabolismo , Corteza Suprarrenal/patología , Neoplasias de la Corteza Suprarrenal/complicaciones , Neoplasias de la Corteza Suprarrenal/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Aldosterona/metabolismo , Ritmo Circadiano/fisiología , Femenino , Humanos , Hiperaldosteronismo/complicaciones , Hiperaldosteronismo/metabolismo , Hiperplasia/complicaciones , Hiperplasia/metabolismo , Hipertensión/complicaciones , Hipertensión/metabolismo , Masculino , Persona de Mediana Edad , Saliva/metabolismo , Adulto JovenRESUMEN
Pheochromocytoma (PCC) is a rare disease, mainly sporadic, but also associated with some familial disorders, with a malignancy frequency of approximately 10%. Only the presence of distant metastases, derived from large pleomorphic chromaffin cells, is widely accepted as a criterion of malignancy. Variable symptoms may be caused by production and release of catecholamines. Since there is no curative treatment for malignant PCC and due to its unfavorable prognosis, assuring quality of life is one of the main therapeutic objectives. Besides a long-term medical treatment of symptoms using selective alpha-1 blockers and nonselective, noncompetitive alpha- and/or beta-blockers, debulking surgery is the first treatment step. In case of a sufficient uptake of (123)I-MIBG treatment with targeted radiation therapy, use of (131)I-MIBG is an option as an adjuvant therapy, following debulking surgery. Chemotherapy should be applied to patients without positive MIBG-scan, with no response to (131)I-MIBG or progression after radionuclide treatment, and especially in cases with high proliferation index. The most effective chemotherapy regimen appears to be the CVD-scheme, including cyclophosphamide, vincristine, and dacarbazine. The so-called targeted molecular therapies with treatment combinations of temozolomide and thalidomide, or sunitinib monotherapy, and novel therapeutic somatostatin analogues have shown promising results and should thus encourage clinical trials to improve the prognosis of metastatic PCC. Within this review the current treatment modalities and novel molecular strategies in the management of this disease are discussed and a treatment algorithm is suggested.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/terapia , Feocromocitoma/terapia , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/patología , Neoplasias de las Glándulas Suprarrenales/cirugía , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia , Humanos , Feocromocitoma/diagnóstico , Feocromocitoma/patología , Feocromocitoma/cirugía , RadioterapiaRESUMEN
Arterial hypertension is highly prevalent and one of the main risk factors for cardiovascular diseases. It has been demonstrated that antihypertensive treatment is effective to prevent cardiovascular events. Advances have been made in this field for 50 years and the knowledge and management of hypertension has been modified continuously with increase of related costs. Therefore hypertension is one of the favorite themes for guidelines and indeed several guidelines have been published on this theme regularly. Despite this, a high percentage of treated hypertensive patients remains uncontrolled. Several reasons have been raised for not implementing guidelines: these guidelines are often little-known because of their large number and their bad distribution. A systematic analysis of the last guidelines showed also they were structurally different with a small percentage of identical references and they provided sometimes different practical conclusions. Finally, clinical inertia is partly responsible for these insufficient results. As the current form of the guidelines has a limited impact on the medical practice, we should find other methods to improve their implementation.
Asunto(s)
Hipertensión/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Competencia Clínica , Francia/epidemiología , Adhesión a Directriz , Humanos , Hipertensión/complicaciones , Hipertensión/epidemiología , Isquemia Miocárdica/etiología , Isquemia Miocárdica/prevención & control , Pautas de la Práctica en Medicina , Prevalencia , Factores de RiesgoRESUMEN
BACKGROUND: Saliva is a readily available biological fluid, making it convenient in diagnosis of diseases and in multi-sampling protocols. Several salivary steroids give a useful index of free plasma levels. Increased incidence of primary aldosteronism (PA) in approximately 10% of the hypertensive population has increased interest in the mineralocorticoid aldosterone. METHODS: A biotinylated-aldosterone tracer and a commercially available antibody are used in a time-resolved fluorescence immunoassay (TR-FIA) to measure salivary aldosterone (SA). Saliva was collected in various multi-sampling protocols: Investigation of diurnal rhythm in healthy and PA patients, ACTH stimulation test and posture test in healthy subjects. RESULTS: Method validation showed a sensitivity of 19 ng/L and intra-/inter-assay precision between 7.2-10.1% and 8.7-15.7%, respectively. SA correlated significantly (y = 0.2995x +/- 0.01, r(2)=0.60) to plasma aldosterone measured by a commercial radioimmunoassay. SA (median; 95%CI) was at 111 (95-127)ng/L in PA (n=84) and 50 (44-56)ng/L in healthy subjects (n=60). After change in posture, aldosterone increased in both, saliva (57 (47-63)ng/L to 95 (84-117)ng/L) and plasma (26 (26-41)ng/L to 135 (110-181)ng/L). Peak levels were reached after 1h, and were higher in females than in males. CONCLUSIONS: SA correlates well to plasma aldosterone and mirrors responses during conditions of stress. SA is significantly higher in PA, and the diurnal rhythm seen in the healthy is blunted in PA. We additionally found gender-dependent differential responses to posture, with higher increases in females. Measurement of aldosterone in saliva presents a useful and convenient method for application in multi-sampling studies.
Asunto(s)
Aldosterona/análisis , Saliva/química , Hormona Adrenocorticotrópica/farmacología , Adulto , Aldosterona/sangre , Aldosterona/aislamiento & purificación , Aldosterona/metabolismo , Artefactos , Estudios de Casos y Controles , Ritmo Circadiano , Femenino , Humanos , Hiperaldosteronismo/sangre , Hiperaldosteronismo/metabolismo , Hiperaldosteronismo/fisiopatología , Inmunoensayo , Masculino , Postura , Reproducibilidad de los Resultados , Saliva/efectos de los fármacos , Saliva/metabolismoRESUMEN
PURPOSE: To determine if trends in antihypertensive drug prescriptions by non-specialist physicians reflect evidence from clinical research. METHODS: Comparison of antihypertensive drugs prescribed to patients before they attended a hypertension clinic in 2001 and 2006, with a special consideration for thiazide diuretics in drug combinations and angiotensin converting enzyme inhibitors (ACEI) in hypertensive patients at high cardiovascular risk (diabetes or secondary prevention). RESULTS: Overall, 1072 hypertensive patients attended the hypertension clinic in 2001 (mean age 53.9 years) and 1040 in 2006 (mean age 55.6 years); both genders were equally represented. Patients already treated when they came at the consultation received a mean number of 2.24 antihypertensive drug classes in 2001 and 2.44 in 2006 (p = 0.002). The prescription of three antihypertensive drug classes increased between 2001 and 2006: Calcium channel blockers from 49 % of treated patients in 2001 to 56 % in 2006 (p = 0.007), angiotensin receptor antagonists from 28 to 42 % (p <0.001) and thiazide diuretics from 31 to 39 % (p = 0.001). Thiazide diuretics were included in 48 % of the antihypertensive combinations in 2001 and 55 % in 2006 (p = 0.02). The prescription of ACEI in patients at high cardiovascular risk remained stable around 31 %. CONCLUSION: Antihypertensive treatments were more intensive in 2006 than 2001, but thiazide diuretics remained underused in drug combinations. The prescription of ACEI did not increase in patients at high cardiovascular risk despite convincing evidence of their benefit.
Asunto(s)
Antihipertensivos/uso terapéutico , Hipertensión/tratamiento farmacológico , Pautas de la Práctica en Medicina/tendencias , Prescripciones/estadística & datos numéricos , Femenino , Francia , Humanos , Masculino , Persona de Mediana Edad , Servicio Ambulatorio en HospitalRESUMEN
We have previously shown that patients with renal fibromuscular dysplasia (FMD) have asymptomatic carotid lesions and that familial forms may occur. The objective of this study was to test whether carotid lesions could be detected in relatives of familial cases. High-resolution echotracking of the carotid artery was performed in 47 relatives of 13 cases from six families. This non-invasive investigation led to a semiquantitative arterial score that was compared with that obtained for 47 controls matched for age and sex and that for 125 sporadic cases. Familial resemblance was tested by using a generalized estimating equation approach taking into account the clustering of scores in families. As expected, FMD cases had a significantly higher score than controls (4.02 vs 2.52, P<10(-5)). Familial cases were not significantly different from sporadic cases. Of interest, the 47 apparently healthy relatives of familial cases had also a high carotid score (4.17), very significantly higher than that of controls (2.52, P<10(-5)) even though lower than the corresponding index FMD cases (4.81, P=0.01). Segregation analysis showed that 52% of the descendants of subjects with a score >4 had a score >4, a proportion consistent with autosomal-dominant transmission of the trait. Altogether these results strengthen the hypothesis of renal FMD being a systemic arterial disease and argue for a familial resemblance that may be due to a major genetic effect. The carotid score obtained by high-resolution echotracking may provide a non-invasive surrogate marker for renal FMD of potential value for use in linkage strategies on large pedigrees.
Asunto(s)
Enfermedades de las Arterias Carótidas/genética , Arteria Carótida Común/patología , Displasia Fibromuscular/genética , Obstrucción de la Arteria Renal/genética , Adulto , Anciano , Análisis de Varianza , Enfermedades de las Arterias Carótidas/complicaciones , Estudios de Casos y Controles , Análisis por Conglomerados , Femenino , Displasia Fibromuscular/complicaciones , Francia , Predisposición Genética a la Enfermedad , Humanos , Hipertensión/etiología , Hipertensión/genética , Masculino , Persona de Mediana Edad , Linaje , Fenotipo , Curva ROC , Análisis de Regresión , Obstrucción de la Arteria Renal/complicaciones , Proyectos de Investigación , Análisis de Supervivencia , Túnica Íntima/patología , Túnica Media/patologíaRESUMEN
The management of a pheochromocytoma during pregnancy is uncommon and is at high risk for both mother and foetus. We report a case of a patient whose first pregnancy was complicated by foetal demise in a context suggestive of preeclampsia. She was diagnosed with pheochromocytoma as she was beginning a second pregnancy. A laparoscopic adrenalectomy was performed in the first trimester of pregnancy, and maternal and neonatal outcome were favourable. This case illustrates the difficulty of diagnosing pheochromocytoma in pregnancy, and the benefits of laparoscopic treatment in the first trimester.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/diagnóstico , Feocromocitoma/diagnóstico , Complicaciones Neoplásicas del Embarazo/diagnóstico , Neoplasias de las Glándulas Suprarrenales/cirugía , Adrenalectomía , Adulto , Femenino , Muerte Fetal , Humanos , Laparoscopía , Feocromocitoma/cirugía , Embarazo , Complicaciones Neoplásicas del Embarazo/cirugía , Resultado del Embarazo , Primer Trimestre del EmbarazoRESUMEN
The methods for diagnosing pheochromocytoma have progressed in 25 years, so changing the clinical, biological and tumoral presentations. The authors compare the features of 199 patients with pheochromocytoma operated between 1975 and 2001 by quartiles. The frequency and known duration of hypertension, plasma adrenaline, the tumour size and proportion of cases which were malignant from the outset, have decreased over the observation period (p < 0.01). The average age and proportion of familial cases or associated with diabetes or those of asymptomatic patients (with incidentaloma), has not changed significantly. The pheochromocytoma were adrenal (104 right, 60 left, 12 bilateral) or ectopic (23) and 13 were malignant from the outset. Over a median 5 year follow-up, 35 pheochromocytomas recurred either in the benign or malignant forms. Recurrences of tumours of the right adrenal were more common than those of the left adrenal gland (p = 0.03). In conclusion, pheochromocytomas are diagnosed earlier, at a stage when the tumours are smaller and less secreting. The higher incidence and recurrence rate of right adrenal pheochromocytoma remain unexplained.